0001437749-26-010700
SEC filingFY2025 delivered $13.1M revenue amid operational disruptions including Q4 Cobalt production shutdowns and supply constraints, yielding a healthy 58.9% gross margin from sales mix changes while generating $86K free cash flow to fund facility upgrades.
Gross profit stood at $7.7 million, delivering a 58.9% margin. The decrease in gross profit percentage versus prior year stemmed from a shift in sales mix, with Calibration products—supported by cobalt-57 recovery—taking a larger share despite their relatively lower margins. Efforts continue to enhance raw material utilization and implement cost controls across operations.
Operating expenses reflected discipline, highlighted by reduced research and development spending from lower product development costs in the Medical Devices segment. Even so, operating income was a -$956K loss, or -7.3% of revenue, primarily due to the revenue decline and compressed profit margins. Net income was -$908K, with diluted EPS at $0.00.
These results underscore Radnostix's ability to maintain gross profitability and cash generation through sales mix adaptation and cost management, even as revenue faced headwinds from necessary infrastructure investments and supplier issues. The completed refurbishments and ongoing supply resolutions set the stage for operational improvements.